ROIV — Roivant Sciences Ltd.
Healthcare · ETF XLV · as of 2026-09-23
Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
Roivant Sciences Ltd.
NMS
Healthcare · Biotechnology
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Price & today
$36.82
ATR(14) 1.49 (4.06%)
| Stock today | -3.66% |
| Sector ETF today | -0.64% |
| Residual (stock-specific) | -3.02% |
Sector correlation
| 20-day correlation with XLV | -0.58 |
| 60-day correlation with XLV | -0.25 |
| Status | DECOUPLING |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $38.70 |
| 20 EMA | $38.25 |
| 50 EMA | $36.58 |
| EMA stack | BULLISH |
| RSI(14) | 45.1 |
| 52-week high distance | +21.40% |
| 52-week low distance | +248.02% |
Signals
| Market F&G | 44.9 |
| Bull% | 13.8% |
| OVTLYR status | SELL (0d) |
| Sector rank | #330 |
| Next earnings | 2026-11-09 (TNS, 46d) |
MarketSmith metrics - our compute
RS Rating
89.5
ADR%
3.8
RMV (tight)
13.0
Ext (ATR>20EMA)
-1.0
Rel Vol
125.0%
U/D 50d
0.79
U/D 25d
0.65
Accum/Dist 25d
5 / 7
EPS YoY
-36.0%
LoD dist
3.0
Off 52w High
13.4%
Above 52w Low
153.9%
1W / 1M
-6.9 / +1.3
Avg $Vol 50d
275.0M
Mkt Cap (B)
26.5
Trend 8/8
YES
Leads Group
YES
Sector XLV
+0.6% 1W
Base len (VCP)
10wk (5/22)
Coil (base shape)
85TVPX
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
P/E (TTM)
-
Fwd P/E
-
PEG
-
Price/Book
4.7
Profit margin
0.0%
ROE
-19.1%
Debt/Equity
2.2
Rev growth
-77.8%
Analyst target
$36 (-3%)
Analyst rating
STRONG_BUY
Institutional %
72.7%
Insider %
22.8%
Float %
74.2%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.
Company data - context read, not entry inputs
Industry rank
89 / 146
Industry
Biotechnology
Float
533.8M
Float turnover 20d
2.0%
Avg $Vol 20d / 50d
409.9M / 275.0M
Days to cover
4.8
Short % float
4.5%
Institutional %
72.7%
Weinstein stage
2
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Nov-24 | -0.30 | - | 4.5 | +23% |
| Feb-25 | -0.20 | - | 9.0 | -42% |
| May-25 | -0.22 | - | 7.6 | -16% |
| Aug-25 | -0.25 | - | 2.2 | -73% |
| Nov-25 | -0.28 | - | 1.6 | -65% |
| Feb-26 | -0.24 | - | 2.0 | -78% |
| May-26 | -0.32 | - | 2.5 | -67% |
| Aug-26 | -0.34 | - | 1.4 | -34% |
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 23 · Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus GlobeNewsWire
- Sep 23 · Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus GlobeNewsWire
- Sep 23 · Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss Yahoo
- Sep 23 · Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus Yahoo
- Sep 23 · Immunovant Ends Autoimmune Skin Disorder Program Benzinga
- Sep 23 · Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint Benzinga
- Sep 22 · Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript Seeking Alpha
- Sep 22 · Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript SeekingAlpha